Anti-B4GALNT1 antibody produced in rabbit

Description

• General description: B4GALNT1 (β-1,4-N-acetyl-galactosaminyl transferase 1) is a GalNAc transferase, and is also called GM2 synthase. This gene is located on human chromosome 12q. Two subunits, linked by disulphide bonds, form a B4GALNT1 homodimer. This protein is transmembrane in nature. Cathepsin D-like protease cleaves this enzyme, in the late Golgi complex, to produce a soluble form.
• Immunogen: Beta-1,4 N-acetylgalactosaminyltransferase 1 recombinant protein epitope signature tag (PrEST)
• Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies® protocols and other useful information.
• Biochem/physiol Actions: B4GALNT1 (β-1,4-N-acetyl-galactosaminyl transferase 1) enzyme catalyses the second step in the biosynthesis of complex gangliosides, such as GM (mono)2, GA (asialo)2 and GD (di)2. Gangliosides are essential components of synaptic plasma membrane, and are essential for the development of central nervous system. Mutations in this gene are linked to the pathogenesis of hereditary spastic paraplegia. It is also expressed in small cell lung carcinoma (SCLC) and neuroblastoma cells. The presence of this protein in post-therapy bone marrow of neuroblastoma patients is related to poor prognosis and survival. Studies in mice show that inactivation of this gene leads to male sterility, as well as degeneration of axons, and suppressed myelination in peripheral and central nervous system.
• Features and Benefits: Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.Every Prestige Antibody is tested in the following ways:IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.Protein array of 364 human recombinant protein fragments.
• Linkage: Corresponding Antigen APREST71972
• Physical form: Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide
• Legal Information: Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany